医药行业周报：BMS在研Opdivo联合Yervoy疗法获FDA优先审评资格

Investment Rating - The industry investment rating is "Positive," with expectations of overall returns exceeding the CSI 300 Index by more than 5% in the next six months [8]. Core Views - The pharmaceutical sector experienced a decline of 1.12% on February 25, 2025, underperforming the CSI 300 Index by 0.01 percentage points, ranking 20th among 31 sub-industries [2]. - Notable performances within sub-industries include vaccines (+0.84%) and blood products (-0.56%), while offline pharmacies (-2.77%) and medical consumables (-2.24%) lagged behind [2]. - Bristol-Myers Squibb (BMS) received FDA priority review status for its combination therapy Opdivo and Yervoy, with a decision expected by June 23, 2025 [3]. - BMS's Opdivo is a PD-1 immune checkpoint inhibitor, and Yervoy targets CTLA-4, used for treating high microsatellite instability or mismatch repair-deficient metastatic colorectal cancer [3]. Company Summaries - Bid Pharma (688073) reported a revenue of 1.102 billion yuan for 2024, a year-on-year increase of 0.93%, with a net profit of 123 million yuan, up 12.07% [4]. - Jiet Bio (688026) achieved a revenue of 557 million yuan, a 20.28% increase, and a net profit of 74 million yuan, up 112.18% [4]. - Teva Bio (688278) reported a revenue of 2.817 billion yuan, a 34.13% increase, and a net profit of 828 million yuan, up 49.00% [4]. - Fuyuan Pharma (601089) received a drug registration certificate for Minoxidil lotion, which will enhance its product line and market competitiveness [4].